EGFR and lung carcinoma: Epidermal growth factor receptor (EGFR) is the best-known target gene for lung cancer, which mutates in a relatively high frequency of 20–30% and tyrosine kinase inhibitors (TKIs) are particularly effective for treating these patients [8–10].